BRD4 and acute myeloid leukemia: dBET1 represents a proteolysis-targeting chimera (PROTAC) targeted against BET family members (73), and targeted BRD4 degradation in acute myeloid leukemia (AML) by dBET1 specifically impairs MYC transcription.